{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:15:08Z","timestamp":1793729708756,"version":"4.6.1"},"update-to":[{"DOI":"10.1002\/14651858.cd003426.pub5","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T00:00:00Z","timestamp":1539907200000}}],"reference-count":111,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003426.pub6","type":"journal-article","created":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T00:24:14Z","timestamp":1539908654000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Drugs for preventing red blood cell dehydration in people with sickle cell disease"],"prefix":"10.1002","volume":"2021","author":[{"given":"Srikanth","family":"Nagalla","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology; UT Southwestern Medical Center; Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir K","family":"Ballas","sequence":"additional","affiliation":[{"name":"Cardeza Foundation for Hematologic Research, Department of Medicine; Jefferson Medical College, Thomas Jefferson University; Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,10,19]]},"reference":[{"issue":"8","key":"10.1002\/14651858.CD003426.pub6-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood-2007-08-110098","article-title":"Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia","volume":"111","author":"Ataga","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD003426.pub6-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1365-2141.2010.08520.x","article-title":"Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease:\u00a0 a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043)","volume":"153","author":"Ataga","year":"2011","journal-title":"British Journal of Haematology"},{"issue":"7","key":"10.1002\/14651858.CD003426.pub6-BIB0003|cit3","first-page":"467","article-title":"Efficacy of zinc therapy in prevention of crisis in sickle cell anemia: a double blind, randomized controlled clinical trial","volume":"43","author":"Gupta","year":"1995","journal-title":"Journal of the Association of Physicians of India"},{"issue":"5","key":"10.1002\/14651858.CD003426.pub6-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/00000441-197305000-00002","article-title":"The effect of megestrol acetate on sickling","volume":"265","author":"Adadevoh","year":"1973","journal-title":"American Journal of the Medical Sciences"},{"issue":"5","key":"10.1002\/14651858.CD003426.pub6-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V90.5.2041","article-title":"RheothRx (Poloxamer 188) injection for the acute painful episode of sickle cell disease: a pilot study","volume":"90","author":"Adams-Graves","year":"1997","journal-title":"Blood"},{"key":"10.1002\/14651858.CD003426.pub6-BIB0006|cit6","unstructured":"Adams-Graves P Kedar A Koshy M Steinberg M Veith R Ward D Rheothrx (Poloxamer 188) injection for the acute painful episode of sickle cell disease (SCD): a pilot study Proceedings of the 30th Annual Meeting of the National Sickle Cell Disease Program; March 1995 1995 118"},{"issue":"Suppl","key":"10.1002\/14651858.CD003426.pub6-BIB0007|cit7","first-page":"410a","article-title":"RheothRx\u00ae (poloxamer 188) injection for the acute painful episode of sickle cell disease","volume":"84","author":"Adams-Graves","year":"1994","journal-title":"Blood"},{"issue":"10 (Suppl 1)","key":"10.1002\/14651858.CD003426.pub6-BIB0008|cit8","first-page":"13a","article-title":"RheothRx (Poloxamer 188) lowers serum LDH during an acute painful episode of sickle cell disease","volume":"88","author":"Emanuele","year":"1996","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub6-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/tropej\/fmh097","article-title":"Clinical evaluation of extract of Cajanus cajan (Ciklavit) in sickle cell anaemia","volume":"51","author":"Akinsulie","year":"2005","journal-title":"Journal of Tropical Pediatrics"},{"issue":"2","key":"10.1002\/14651858.CD003426.pub6-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"97","DOI":"10.5144\/0256-4947.1999.97","article-title":"Isoxsuprine in the treatment of sickle cell painful crises: a double-blind comparative study with narcotic analgesia","volume":"19","author":"Al-Jam'a","year":"1999","journal-title":"Annals of Saudi Medicine"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub6-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000084675","article-title":"Inefficacy of piracetam in the prevention of painful crises in children and adolescents with sickle cell disease","volume":"113","author":"Alvim","year":"2005","journal-title":"Acta Haematologica"},{"key":"10.1002\/14651858.CD003426.pub6-BIB0012|cit12","unstructured":"Ataga KI Orringer EP Styles L Vichinsky E Swerdlow P Davis GA A phase 1B randomized, double-blind, placebo-controlled, single-dose, dose-escalation study of IC 17043 in patients with sickle cell disease (SCD) Proceedings of the 30th Annual Meeting of the National Sickle Cell Disease Program 2002 41a"},{"issue":"11 (Part 1 of 2","key":"10.1002\/14651858.CD003426.pub6-BIB0013|cit13","first-page":"454a","article-title":"A phase 1B randomized, double-blind, placebo-controlled, single-dose, dose-escalation study of ICA-17043 in patients with sickle cell disease (SCD)","volume":"100","author":"Ataga","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub6-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1046\/j.1365-2141.1996.d01-1744.x","article-title":"Tucaresol increases oxygen affinity and reduces haemolysis in subjects with sickle cell anaemia","volume":"93","author":"Arya","year":"1996","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD003426.pub6-BIB0015|cit15","doi-asserted-by":"crossref","unstructured":"Bartolucci P El Murr T Roudot-Thoraval F Habibi A Santin A Renaud B A randomized, controlled clinical trial of ketoprofen for sickle-cell disease vaso-occlusive crises in adults Blood 2009 114 18 3742 7 93124810","DOI":"10.1182\/blood-2009-06-227330"},{"key":"10.1002\/14651858.CD003426.pub6-BIB0016|cit16","unstructured":"Beatty JR Calamaras DM Gamerman SE Nuuhiwa JKB Schmidt NA The effect of guided imagery on pain in children Proceedings of the 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA 2007 346"},{"issue":"5","key":"10.1002\/14651858.CD003426.pub6-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/blood.V67.5.1442.1442","article-title":"A collaborative, double-blind randomized study of cetiedil citrate in sickle cell crisis","volume":"67","author":"Benjamin","year":"1986","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD003426.pub6-BIB0018|cit18","first-page":"403","article-title":"Pentoxifylline (Trental) has no significant effect on laboratory parameters in sickle cell disease","volume":"31","author":"Billett","year":"1989","journal-title":"Nouvelle Revue Francaise d'Hematologie"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub6-BIB0019|cit19","first-page":"207","article-title":"Acute painful sickle-cell crises in children: a double-blind, placebo-controlled evaluation of efficacy and safety of cetiedil","volume":"20","author":"Cabannes","year":"1983","journal-title":"Clinical Trials Journal"},{"key":"10.1002\/14651858.CD003426.pub6-BIB0020|cit20","first-page":"199","article-title":"Clinical and biological double-blind-study of Ticlopidine in preventive treatment of sickle cell disease crises","volume":"15","author":"Cabannes","year":"1984","journal-title":"Agents and Actions Supplements"},{"issue":"5","key":"10.1002\/14651858.CD003426.pub6-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0010-7824(97)00156-X","article-title":"Effect of Depo-Provera\u00ae or Microgynon\u00ae on the painful crises of sickle cell anemia patients","volume":"56","author":"De Abood","year":"1997","journal-title":"Contraception"},{"issue":"8292","key":"10.1002\/14651858.CD003426.pub6-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(82)90320-8","article-title":"Medroxyprogesterone acetate and homozygous sickle cell disease","volume":"2","author":"De Ceulaer","year":"1982","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003426.pub6-BIB0023|cit23","unstructured":"De Ceulaer K Gruber C Serjeant G Effect of depo-provera on the haematological and clinical features of homozygous sickle cell disease Proceedings of the Commonwealth Caribbean Medical Research Council, 27th Scientific Meeting; 1982 April 14-17; Trinidad and Tobago 1982 47"},{"issue":"1","key":"10.1002\/14651858.CD003426.pub6-BIB0024|cit24","first-page":"35","article-title":"Intravenous oxypentifylline and the painful crisis of sickle cell disease","volume":"10","author":"De Ceulaer","year":"1990","journal-title":"Clinical Hemorheology"},{"issue":"2","key":"10.1002\/14651858.CD003426.pub6-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0021-9681(82)90115-1","article-title":"A double-blind randomized trial of low-dose urea to prevent sickle cell crises","volume":"35","author":"Gail","year":"1982","journal-title":"Journal of Chronic Diseases"},{"key":"10.1002\/14651858.CD003426.pub6-BIB0026|cit26","doi-asserted-by":"crossref","unstructured":"Gladwin MT Kato GJ Weiner D Onyekwere OC Dampier C Hsu L Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial JAMA 2011 305 9 893 902 93124810","DOI":"10.1001\/jama.2011.235"},{"issue":"11","key":"10.1002\/14651858.CD003426.pub6-BIB0027|cit27","first-page":"2824a","article-title":"Assessment of ketoprofen for acute vaso-occlusive crisis in adult patients with sickle cell disease. A randomized double blind monocentric study","volume":"102","author":"Godeau","year":"2003","journal-title":"Blood"},{"issue":"7750","key":"10.1002\/14651858.CD003426.pub6-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/S0140-6736(72)90359-5","article-title":"Steroid treatment in the prevention of painful episodes in sickle-cell disease","volume":"1","author":"Isaacs","year":"1972","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub6-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000208633","article-title":"The effect of certain lipid substances on sickling","volume":"45","author":"Isaacs","year":"1971","journal-title":"Acta Haematologica"},{"issue":"9088","key":"10.1002\/14651858.CD003426.pub6-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(97)08462-6","article-title":"Randomised trial of oral morphine for painful episodes of sickle-cell disease in children","volume":"350","author":"Jacobson","year":"1997","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD003426.pub6-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.clpt.2003.10.007","article-title":"Systemic exposure to morphine and the risk of acute chest syndrome in sickle cell disease","volume":"75","author":"Kopesky","year":"2004","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD003426.pub6-BIB0032|cit32","first-page":"213","article-title":"Beneficial effects of Ticlopidine on cardiopulmonary function of sickle cell patients not in crisis","volume":"15","author":"Lonsdorfer","year":"1984","journal-title":"Agents and Actions Supplements"},{"issue":"1","key":"10.1002\/14651858.CD003426.pub6-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2141.1969.tb00391.x","article-title":"A double-blind trial of a phenothiazine compound in the treatment of clinical crisis of sickle cell anaemia","volume":"16","author":"Mahmood","year":"1969","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD003426.pub6-BIB0034|cit34","unstructured":"Manion C Parkhurst JB Ogle B Johnson A Edmundson A Aspartame inhibits hypoxia-induced sickling of erythrocytes in patients with sickle cell disease Proceedings of the 24th Annual Meeting of the National Sickle Cell Disease Program 2000 172a"},{"issue":"5","key":"10.1002\/14651858.CD003426.pub6-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1067\/mcp.2001.115141","article-title":"Aspartame effect in sickle cell anemia","volume":"69","author":"Manion","year":"2001","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"5&6","key":"10.1002\/14651858.CD003426.pub6-BIB0036|cit36","first-page":"277","article-title":"Placebo controlled double-blind study of pentoxifylline in sickle cell disease patients","volume":"18","author":"Manrique","year":"1987","journal-title":"Journal of Medicine"},{"key":"10.1002\/14651858.CD003426.pub6-BIB0037|cit37","unstructured":"Orringer E Huffman J Johnson A Jones S Whitney J Brockenbrough S A clinical study of the safety, pharmacokinetics and pharmacodynamics of intravenous infusions of 12C79 in sickle cell disease patients not in crisis Proceedings of the 16th Annual Meeting of the National Sickle Cell Disease Program; March 1991 1991 112"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003426.pub6-BIB0038|cit38","first-page":"69a","article-title":"Phase 1 study of BW 12C in sickle cell disease (SCD) patients not in crisis","volume":"5","author":"Orringer","year":"1988","journal-title":"Blood"},{"key":"10.1002\/14651858.CD003426.pub6-BIB0039|cit39","unstructured":"Orringer EP Binder EA Thomas RP Blythe DS Bustrack JA Schroeder DH Phase I study of 12C79 in sickle cell disease (SCD) patients not in crisis Proceedings of the 14th Annual Meeting of the National Sickle Cell Disease Program 1989 57"},{"issue":"2","key":"10.1002\/14651858.CD003426.pub6-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000207105","article-title":"Therapeutic effect of aspirin in sickle cell anaemia","volume":"66","author":"Osamo","year":"1981","journal-title":"Acta Haematologica"},{"issue":"2","key":"10.1002\/14651858.CD003426.pub6-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0022-3476(68)80083-6","article-title":"Failure of promazine HCl to prevent the painful episodes in sickle cell anemia","volume":"73","author":"Oski","year":"1968","journal-title":"Journal of Pediatrics"},{"issue":"3","key":"10.1002\/14651858.CD003426.pub6-BIB0042|cit42","first-page":"249","article-title":"Therapeutic effect of diflusinal as prophylaxis in sickle cell anaemia","volume":"24","author":"Oyewo","year":"1987","journal-title":"Clinical Trials Journal"},{"issue":"1","key":"10.1002\/14651858.CD003426.pub6-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ajh.10321","article-title":"Effects of N-acetylcysteine on dense cell formation in sickle cell disease","volume":"73","author":"Pace","year":"2003","journal-title":"American Journal of Hematology"},{"issue":"5","key":"10.1002\/14651858.CD003426.pub6-BIB0044|cit44","first-page":"834","article-title":"Effectiveness of treatment during osteoarticular pain crises in drepanocytosis; based on the example of pentoxifylline","volume":"80","author":"Pichard","year":"1987","journal-title":"Bulletin de la Societe de Pathologie Exotique et de ses Filiales (Paris)"},{"key":"10.1002\/14651858.CD003426.pub6-BIB0045|cit45","unstructured":"El-Hazmi AF Warsy AS Al-Fawaz I Farid M Refai S Opawoye AD Piracetam in the treatment of sickle cell disease Proceedings of the 20th Annual Meeting of the National Sickle Cell Disease Program 1995 162a"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub6-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000203788","article-title":"Piracetam is useful in the treatment of children with sickle cell disease","volume":"96","author":"El-Hazmi","year":"1996","journal-title":"Acta Haematologica"},{"issue":"1","key":"10.1002\/14651858.CD003426.pub6-BIB0047|cit47","first-page":"22","article-title":"Piracetam for the treatment of sickle cell disease in children - a double blind test","volume":"19","author":"The Piracetam Study Group","year":"1998","journal-title":"Saudi Medical Journal"},{"issue":"8","key":"10.1002\/14651858.CD003426.pub6-BIB0048|cit48","first-page":"608","article-title":"Haemorheological treatment of painful sickle cell crises: use of pentoxifylline","volume":"39","author":"Poflee","year":"1991","journal-title":"Journal of the Association of Physicians India"},{"issue":"2","key":"10.1002\/14651858.CD003426.pub6-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1160\/Th06-12-0718","article-title":"Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial","volume":"98","author":"Qari","year":"2007","journal-title":"Thrombosis and Haemostasis"},{"issue":"3","key":"10.1002\/14651858.CD003426.pub6-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2165\/00003088-199222030-00006","article-title":"Prediction of diltiazem plasma concentration curves from limited measurements using compliance data","volume":"22","author":"Rubio","year":"1992","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1002\/14651858.CD003426.pub6-BIB0051|cit51","first-page":"47","article-title":"Scoring system in a pilot effectiveness study of patients with sickle cell anemia","volume":"6","author":"Rubio","year":"1992","journal-title":"Journal of Clinical Research and Pharmacoepidemiology"},{"issue":"3","key":"10.1002\/14651858.CD003426.pub6-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1055\/s-0038-1661088","article-title":"A double-blind trial of Ticlopidine in sickle cell disease","volume":"51","author":"Semple","year":"1984","journal-title":"Thrombosis and Haemostasis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003426.pub6-BIB0053|cit53","first-page":"298","article-title":"Hydroxyurea treatment of sickle cell diseases causes megaloblastic transformation of the bone marrow that is responsible for the increase of the mean corpuscular volume","volume":"92","author":"Silva-Pinto","year":"2007","journal-title":"Haematologica"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub6-BIB0054|cit54","first-page":"320","article-title":"Double blind randomised clinical trial of pentoxiphyllin in vaso-occlusive sickle cell crisis","volume":"41","author":"Teuscher","year":"1989","journal-title":"Tropical and Geographical Medicine"},{"issue":"9226","key":"10.1002\/14651858.CD003426.pub6-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(00)02508-3","article-title":"Antisickling activity of sodium cromoglicate in sickle-cell disease [letter]","volume":"356","author":"Toppet","year":"2000","journal-title":"Lancet"},{"issue":"9","key":"10.1002\/14651858.CD003426.pub6-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1001\/jama.1974.03230340022022","article-title":"Clinical trials of therapy for sickle cell vaso-occlusive crises","volume":"228","author":"Cooperative Urea Trials Group","year":"1974","journal-title":"Journal of the American Medical Association"},{"issue":"9","key":"10.1002\/14651858.CD003426.pub6-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1001\/jama.1974.03230340027023","article-title":"Treatment of sickle cell crisis with urea in invert sugar. A controlled trial","volume":"228","author":"Cooperative Urea Trials Group","year":"1974","journal-title":"JAMA"},{"issue":"9","key":"10.1002\/14651858.CD003426.pub6-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1001\/jama.1974.03230340031024","article-title":"Controlled clinical trials and cooperative study of intravenously administered alkali","volume":"228","author":"Cooperative Urea Trials Group","year":"1974","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD003426.pub6-BIB0059|cit59","doi-asserted-by":"crossref","unstructured":"Uzun B Kekec Z Gurkan E Efficacy of tramadol vs meperidine in vasoocclusive sickle cell crisis American Journal of Emergency Medicine 2010 28 4 445 9 93124810","DOI":"10.1016\/j.ajem.2009.01.016"},{"key":"10.1002\/14651858.CD003426.pub6-BIB0060|cit60","unstructured":"Wallen GR Handel D Mendoza J Chestnut W Nichols J Yates J A randomized pilot study exploring hypnosis as a pain and symptom management strategy in patients with sickle cell disease 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007 261"},{"issue":"2","key":"10.1002\/14651858.CD003426.pub6-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1211\/fact.2002.00158","article-title":"Indigenous Nigerian medicinal plants may be useful in the management of sickle-cell disorder","volume":"7","author":"Fonnebo","year":"2002","journal-title":"Focus on Alternative and Complementary Therapies"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub6-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1078\/0944-7113-00040","article-title":"Double-blind, placebo-controlled, randomised cross-over clinical trial of Niprisan in patients with sickle cell disorder","volume":"8","author":"Wambebe","year":"2001","journal-title":"Phytomedicine"},{"key":"10.1002\/14651858.CD003426.pub6-BIB0063|cit63","unstructured":"Wambebe C Chemistry and clinical evaluation of NIPRISAN in patients with sickle cell anemia Proceedings of the 30th Annual Meeting of the National Sickle Cell Disease Program 2002 46a"},{"issue":"1","key":"10.1002\/14651858.CD003426.pub6-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0011-393X(01)80039-4","article-title":"Efficacy of niprisan in the prophylactic management of patients with sickle cell disease","volume":"62","author":"Wambebe","year":"2001","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"11 Pt 1","key":"10.1002\/14651858.CD003426.pub6-BIB0065|cit65","first-page":"11a","article-title":"Inhaled nitric oxide for treatment of acute vaso-occlusive crisis in sickle cell disease","volume":"100","author":"Weiner","year":"2002","journal-title":"Blood"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD003426.pub6-BIB0066|cit66","first-page":"86A","article-title":"Effectiveness and safety of inhaled nitric oxide for the treatment of vaso-occlusive crisis in pediatric sickle cell disease","volume":"51","author":"Weiner","year":"2002","journal-title":"Pediatric Research"},{"issue":"9","key":"10.1002\/14651858.CD003426.pub6-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/jama.289.9.1136","article-title":"Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease","volume":"289","author":"Weiner","year":"2003","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD003426.pub6-BIB0068|cit68","unstructured":"Wynn L Debenham E Faughnan L Martin B Kelly T Reed C Recruitment in the baby hug pediatric hydroxyurea phase 3 clinical trial 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA 2007 245"},{"issue":"1","key":"10.1002\/14651858.CD003426.pub6-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000206360","article-title":"Treatment of sickle cell diseases with aspirin","volume":"72","author":"Zago","year":"1984","journal-title":"Acta Haematologica"},{"issue":"11","key":"10.1002\/14651858.CD003426.pub6-BIB0070|cit70","first-page":"Parts 1 and 2","article-title":"Nitric oxide restores the erythrocyte density of the SAD mouse model of sickle cell disease","volume":"96","author":"Adrie","year":"2000","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD003426.pub6-BIB0071|cit71","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006111.pub2","article-title":"Piracetam for reducing the incidence of painful sickle cell disease crises","author":"Al Hajeri","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD003426.pub6-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/ajh.2830320206","article-title":"Effect of hydroxyurea on the rheological properties of sickle erythrocytes in vivo","volume":"32","author":"Ballas","year":"1989","journal-title":"American Journal of Hematology"},{"issue":"11","key":"10.1002\/14651858.CD003426.pub6-BIB0073|cit73","first-page":"Parts 1 and 2","article-title":"Hydration of sickle erythrocytes using a naturally occurring sodium ionophore","volume":"96","author":"Ballas","year":"2000","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD003426.pub6-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1182\/blood.V95.5.1842.005a37_1842_1848","article-title":"Volume control in sickle cells is facilitated by novel anion conductance inhibitor NS1652","volume":"95","author":"Bennekou","year":"2000","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD003426.pub6-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1182\/blood.V97.5.1451","article-title":"Treatment with NS3623, a novel Cl-conductance blocker, amiliorates erythrocyte dehydration in transgenic SAD mice: a possible new therapeutic approach for sickle cell disease","volume":"97","author":"Bennekou","year":"2001","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD003426.pub6-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood.V70.6.1810.1810","article-title":"Inhibition of K transport by divalent cations in sickle erythrocytes","volume":"70","author":"Brugnara","year":"1987","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD003426.pub6-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1172\/JCI116597","article-title":"Inhibition of Ca2+activated K + transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives","volume":"92","author":"Brugnara","year":"1993","journal-title":"Journal of Clinical Investigation"},{"issue":"2","key":"10.1002\/14651858.CD003426.pub6-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/00062752-199502020-00005","article-title":"Red cell dehydration in pathophysiology and treatment of sickle cell disease","volume":"2","author":"Brugnara","year":"1995","journal-title":"Current Opinion in Hematology"},{"issue":"5","key":"10.1002\/14651858.CD003426.pub6-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1172\/JCI118537","article-title":"Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease","volume":"97","author":"Brugnara","year":"1996","journal-title":"Journal of Clinical Investigation"},{"issue":"20","key":"10.1002\/14651858.CD003426.pub6-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia","volume":"332","author":"Charache","year":"1995","journal-title":"New England Journal of Medicine"},{"issue":"7109","key":"10.1002\/14651858.CD003426.pub6-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1136\/bmj.315.7109.656","article-title":"Management of patients with sickle cell disease","volume":"315","author":"Davies","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub6-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1172\/JCI117149","article-title":"Treatment with oral clotrimazole blocks Ca(2+)-activated K+ transport and reverses erythrocyte dehydration in transgenic SAD mice. A model for therapy of sickle cell disease.","volume":"93","author":"Franceschi","year":"1994","journal-title":"Journal of Clinical Investigation"},{"issue":"1","key":"10.1002\/14651858.CD003426.pub6-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"11","key":"10.1002\/14651858.CD003426.pub6-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1182\/blood.V91.11.4373","article-title":"The efficacy of reducing agents or antioxidants in blocking the formation of dense cells and irreversibly sickled cells in vitro","volume":"91","author":"Gibson X","year":"1998","journal-title":"Blood"},{"issue":"2-3","key":"10.1002\/14651858.CD003426.pub6-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0014-5793(00)01930-X","article-title":"Effect of dimethyl adipimidate on K+ transport and shape change in red blood cells from sickle cell patients","volume":"480","author":"Gibson","year":"2000","journal-title":"FEBS Letters"},{"issue":"1","key":"10.1002\/14651858.CD003426.pub6-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1136\/jcp.40.1.99","article-title":"Use of piracetam improves sickle cell deformability in vitro and in vivo","volume":"40","author":"Gini","year":"1987","journal-title":"Journal of Clinical Pathology"},{"key":"10.1002\/14651858.CD003426.pub6-BIB0087|cit87","first-page":"477","volume-title":"Thalassemia: pathophysiology and management, part A","volume":"23","author":"Gupta","year":"1987"},{"issue":"1","key":"10.1002\/14651858.CD003426.pub6-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1365-2141.2007.06884.x","article-title":"Phase I study of magnesium pidolate in combination with hydroxycarbamide for children with sickle cell anaemia","volume":"140","author":"Hankins","year":"2008","journal-title":"British Journal of Haematology"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub6-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1046\/j.1365-2141.1999.01275.x","article-title":"Mapping the prevalence of sickle cell disease and beta thalassaemia in England: estimating and validating ethnic-specific rates","volume":"104","author":"Hickman","year":"1999","journal-title":"British Journal of Haematology"},{"issue":"7414","key":"10.1002\/14651858.CD003426.pub6-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD003426.pub6-BIB0091|cit91","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002202","article-title":"Hydroxyurea for sickle cell disease","author":"Jones","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7850","key":"10.1002\/14651858.CD003426.pub6-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(74)92518-5","article-title":"Plasma-zinc in sickle cell-anaemia [letter]","volume":"1","author":"Karayalcin","year":"1974","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD003426.pub6-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1542\/peds.84.3.500","article-title":"Mortality in children and adolescents with sickle cell disease","volume":"84","author":"Leikin","year":"1989","journal-title":"Pediatrics"},{"issue":"2","key":"10.1002\/14651858.CD003426.pub6-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/ajh.2830100203","article-title":"Effect of zinc supplementation on serum testosterone level in adult male sickle cell anemia subjects","volume":"10","author":"Prasad","year":"1981","journal-title":"American Journal of Hematology"},{"issue":"3","key":"10.1002\/14651858.CD003426.pub6-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/(SICI)1096-8652(199907)61:3<194::AID-AJH6>3.0.CO;2-C","article-title":"Effect of zinc supplementation on incidence of infections and hospital admissions in sickle cell disease (SCD)","volume":"61","author":"Prasad","year":"1999","journal-title":"American Journal of Hematology"},{"issue":"11 (Pt 1 and 2)","key":"10.1002\/14651858.CD003426.pub6-BIB0096|cit96","article-title":"Decreased exhaled nitric oxide (NO) in patients with sickle cell disease","volume":"96","author":"Qureshi","year":"2000","journal-title":"Blood"},{"key":"10.1002\/14651858.CD003426.pub6-BIB0097|cit97","unstructured":"Rivera A Brugnara C Vaso-active molecules modulate Gardos channel activity and hydration state of normal and sickle erythrocytes Blood 2000"},{"issue":"11 (Pt 1 and 2)","key":"10.1002\/14651858.CD003426.pub6-BIB0098|cit98","article-title":"Arginine supplementation of sickle transgenic mice: effects on red cell density and potassium transport","volume":"96","author":"Romero","year":"2000","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub6-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1182\/blood.V99.4.1103","article-title":"Arginine supplementation of sickle transgenic mice reduces red cell density and Gardos channel activity","volume":"99","author":"Romero","year":"2002","journal-title":"Blood"},{"issue":"7679","key":"10.1002\/14651858.CD003426.pub6-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S0140-6736(70)92067-2","article-title":"Oral zinc sulphate in sickle-cell ulcers","volume":"2","author":"Serjeant","year":"1970","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003426.pub6-BIB0101|cit101","volume-title":"Sickle cell disease","author":"Serjeant","year":"1992"},{"issue":"11 (Pt 1 and 2)","key":"10.1002\/14651858.CD003426.pub6-BIB0102|cit102","article-title":"A novel Gardos channel inhibitor, ICA-17043, prevents red blood cell dehydration in vitro and in a mouse model (SAD) of sickle cell disease","volume":"96","author":"Stocker","year":"2000","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD003426.pub6-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1182\/blood-2002-05-1433","article-title":"ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice","volume":"101","author":"Stocker","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD003426.pub6-BIB0104|cit104","first-page":"779","article-title":"Action of piracetam on cation flux and deformability of sickle cells","volume":"8","author":"Stone","year":"1988","journal-title":"Clinical Hemorheology"},{"issue":"5","key":"10.1002\/14651858.CD003426.pub6-BIB0105|cit105","first-page":"535","article-title":"Effect of Piracetam on Ca2+-induced K+ efflux from sickle cells","volume":"10","author":"Stuart","year":"1990","journal-title":"Clinical Hemorheology"},{"issue":"2","key":"10.1002\/14651858.CD003426.pub6-BIB0106|cit106","first-page":"203","article-title":"Rheological consequences of sickle-cell dehydration","volume":"12","author":"Stuart","year":"1992","journal-title":"Clinical Hemorheology"},{"key":"10.1002\/14651858.CD003426.pub6-BIB0107|cit107","unstructured":"Zemel B Kawchak D Fung E Ohene-Frempong K Stallings V Zinc supplementation and linear growth in children with sickle cell disease: a pilot study Proceedings of the 25th Annual Meting of the National Sickle Cell Disease Program; April 2001; New York 2001 Abst #232"},{"issue":"1","key":"10.1002\/14651858.CD003426.pub6-BIB0108|cit108","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003426.pub3","article-title":"Drugs for preventing red blood cell dehydration in people with sickle cell disease","author":"Nagalla","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD003426.pub6-BIB0109|cit109","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003426.pub4","article-title":"Drugs for preventing red blood cell dehydration in people with sickle cell disease","author":"Nagalla","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub6-BIB0110|cit110","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003426.pub2","article-title":"Drugs for preventing red blood cell dehydration in people with sickle cell disease","author":"Riddington","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub6-BIB0111|cit111","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003426.pub2","article-title":"Drugs for preventing red blood cell dehydration in people with sickle cell disease","author":"Singh","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD003426.pub6\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T14:45:37Z","timestamp":1720709137000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD003426.pub6"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,10,19]]},"references-count":111,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003426.pub6","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,19]]}}}